Cargando…
The therapeutic landscape of HIV-1 via genome editing
Current treatment for HIV-1 largely relies on chemotherapy through the administration of antiretroviral drugs. While the search for anti-HIV-1 vaccine remain elusive, the use of highly active antiretroviral therapies (HAART) have been far-reaching and has changed HIV-1 into a manageable chronic infe...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513397/ https://www.ncbi.nlm.nih.gov/pubmed/28705213 http://dx.doi.org/10.1186/s12981-017-0157-8 |
_version_ | 1783250653481533440 |
---|---|
author | Kwarteng, Alexander Ahuno, Samuel Terkper Kwakye-Nuako, Godwin |
author_facet | Kwarteng, Alexander Ahuno, Samuel Terkper Kwakye-Nuako, Godwin |
author_sort | Kwarteng, Alexander |
collection | PubMed |
description | Current treatment for HIV-1 largely relies on chemotherapy through the administration of antiretroviral drugs. While the search for anti-HIV-1 vaccine remain elusive, the use of highly active antiretroviral therapies (HAART) have been far-reaching and has changed HIV-1 into a manageable chronic infection. There is compelling evidence, including several side-effects of ARTs, suggesting that eradication of HIV-1 cannot depend solely on antiretrovirals. Gene therapy, an expanding treatment strategy, using RNA interference (RNAi) and programmable nucleases such as meganuclease, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and clustered regularly interspaced short palindromic repeats/CRISPR-associated proteins (CRISPR–Cas9) are transforming the therapeutic landscape of HIV-1. TALENS and ZFNS are structurally similar modular systems, which consist of a FokI endonuclease fused to custom-designed effector proteins but have been largely limited, particularly ZFNs, due to their complexity and cost of protein engineering. However, the newly developed CRISPR–Cas9 system, consists of a single guide RNA (sgRNA), which directs a Cas9 endonuclease to complementary target sites, and serves as a superior alternative to the previous protein-based systems. The techniques have been successfully applied to the development of better HIV-1 models, generation of protective mutations in endogenous/host cells, disruption of HIV-1 genomes and even reactivating latent viruses for better detection and clearance by host immune response. Here, we focus on gene editing-based HIV-1 treatment and research in addition to providing perspectives for refining these techniques. |
format | Online Article Text |
id | pubmed-5513397 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55133972017-07-19 The therapeutic landscape of HIV-1 via genome editing Kwarteng, Alexander Ahuno, Samuel Terkper Kwakye-Nuako, Godwin AIDS Res Ther Review Current treatment for HIV-1 largely relies on chemotherapy through the administration of antiretroviral drugs. While the search for anti-HIV-1 vaccine remain elusive, the use of highly active antiretroviral therapies (HAART) have been far-reaching and has changed HIV-1 into a manageable chronic infection. There is compelling evidence, including several side-effects of ARTs, suggesting that eradication of HIV-1 cannot depend solely on antiretrovirals. Gene therapy, an expanding treatment strategy, using RNA interference (RNAi) and programmable nucleases such as meganuclease, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and clustered regularly interspaced short palindromic repeats/CRISPR-associated proteins (CRISPR–Cas9) are transforming the therapeutic landscape of HIV-1. TALENS and ZFNS are structurally similar modular systems, which consist of a FokI endonuclease fused to custom-designed effector proteins but have been largely limited, particularly ZFNs, due to their complexity and cost of protein engineering. However, the newly developed CRISPR–Cas9 system, consists of a single guide RNA (sgRNA), which directs a Cas9 endonuclease to complementary target sites, and serves as a superior alternative to the previous protein-based systems. The techniques have been successfully applied to the development of better HIV-1 models, generation of protective mutations in endogenous/host cells, disruption of HIV-1 genomes and even reactivating latent viruses for better detection and clearance by host immune response. Here, we focus on gene editing-based HIV-1 treatment and research in addition to providing perspectives for refining these techniques. BioMed Central 2017-07-14 /pmc/articles/PMC5513397/ /pubmed/28705213 http://dx.doi.org/10.1186/s12981-017-0157-8 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Kwarteng, Alexander Ahuno, Samuel Terkper Kwakye-Nuako, Godwin The therapeutic landscape of HIV-1 via genome editing |
title | The therapeutic landscape of HIV-1 via genome editing |
title_full | The therapeutic landscape of HIV-1 via genome editing |
title_fullStr | The therapeutic landscape of HIV-1 via genome editing |
title_full_unstemmed | The therapeutic landscape of HIV-1 via genome editing |
title_short | The therapeutic landscape of HIV-1 via genome editing |
title_sort | therapeutic landscape of hiv-1 via genome editing |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513397/ https://www.ncbi.nlm.nih.gov/pubmed/28705213 http://dx.doi.org/10.1186/s12981-017-0157-8 |
work_keys_str_mv | AT kwartengalexander thetherapeuticlandscapeofhiv1viagenomeediting AT ahunosamuelterkper thetherapeuticlandscapeofhiv1viagenomeediting AT kwakyenuakogodwin thetherapeuticlandscapeofhiv1viagenomeediting AT kwartengalexander therapeuticlandscapeofhiv1viagenomeediting AT ahunosamuelterkper therapeuticlandscapeofhiv1viagenomeediting AT kwakyenuakogodwin therapeuticlandscapeofhiv1viagenomeediting |